Revolution Medicines (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 5,569 Shares of Stock

by · The Markets Daily

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Stephen Kelsey sold 5,569 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $1,109,567.56. Following the transaction, the insider directly owned 286,307 shares in the company, valued at $57,043,806.68. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stephen Michael Kelsey also recently made the following trade(s):

  • On Friday, September 11th, Stephen Kelsey sold 92,531 shares of Revolution Medicines stock. The shares were sold at an average price of $202.36, for a total transaction of $18,724,573.16.

Revolution Medicines Stock Performance

RVMD stock opened at $190.95 on Friday. The company has a market capitalization of $40.93 billion, a P/E ratio of -21.65 and a beta of 1.40. The company has a 50-day simple moving average of $199.57 and a 200 day simple moving average of $159.57. Revolution Medicines, Inc. has a fifty-two week low of $42.18 and a fifty-two week high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the company posted ($1.31) EPS. Sell-side analysts predict that Revolution Medicines, Inc. will post -8.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Mizuho raised their price objective on shares of Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, July 6th. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Revolution Medicines in a research note on Thursday, August 27th. Sanford C. Bernstein lifted their price target on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. UBS Group lifted their price target on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, August 28th. Finally, Truist Financial boosted their price objective on Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $226.17.

Check Out Our Latest Stock Analysis on RVMD

Hedge Funds Weigh In On Revolution Medicines

Hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC acquired a new stake in Revolution Medicines during the second quarter valued at approximately $626,000. MCF Advisors LLC bought a new stake in Revolution Medicines during the second quarter worth approximately $78,000. National Pension Service acquired a new position in Revolution Medicines in the second quarter worth approximately $51,241,000. Engineers Gate Manager LP grew its position in Revolution Medicines by 144.0% in the second quarter. Engineers Gate Manager LP now owns 7,380 shares of the company’s stock worth $1,382,000 after buying an additional 4,356 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Revolution Medicines in the second quarter valued at $278,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

  • Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
  • Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
  • Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.

Read More